Biostem Technologies, Inc. (NASDAQ:BSEM) Stock Short Interest Rises 239.1%

Biostem Technologies, Inc. (NASDAQ:BSEM) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totaling 333,843 shares, an increase of 239.1% from the September 30th total of 98,453 shares. Currently, 1.8% of the company’s stock are short sold. Based on an average daily volume of 110,434 shares, the short-interest ratio is presently 3.0 days.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Weiss Ratings assumed coverage on Biostem Technologies in a report on Wednesday, August 19th. They issued a “sell (d-)” rating on the stock. Wall Street Zen upgraded Biostem Technologies to a “sell” rating in a research note on Saturday, September 5th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Biostem Technologies currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Biostem Technologies Stock Down 13.2%

Shares of BSEM opened at $1.12 on Friday. The stock has a 50 day moving average price of $3.08 and a 200 day moving average price of $4.20. The company has a market capitalization of $20.91 million, a price-to-earnings ratio of -0.70 and a beta of 0.17. Biostem Technologies has a 52-week low of $1.11 and a 52-week high of $8.40.

Biostem Technologies (NASDAQ:BSEM) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.02). The company had revenue of $7.90 million during the quarter, compared to analysts’ expectations of $6.35 million. Biostem Technologies had a negative net margin of 76.02% and a negative return on equity of 60.22%. On average, equities analysts anticipate that Biostem Technologies will post -1.90 EPS for the current fiscal year.

About Biostem Technologies

BioStem Technologies, Inc is a biotechnology company focused on regenerative medicine and biologic tissue products. The company develops, manufactures and commercializes human tissue allografts intended to support wound care, tissue repair and other medical applications.

Its product portfolio includes placental- and birth-tissue-derived products, such as amniotic membrane and umbilical cord allografts. These products are marketed for use by healthcare providers in areas including wound management, surgical procedures and related regenerative-care applications.

BioStem Technologies serves the U.S.